Despite the potential impact of missed visits on the outcomes of neuromodulation treatments, it is not clear how this issue has been addressed in clinical trials. Given this gap in the literature, we reviewed articles on non-invasive brain stimulation in participants with depression or chronic pain, and investigated how missed visits were handled.
Introduction
Transcranial direct current stimulation (tDCS) and transcranial magnetic stimulation (TMS) use electrical or magnetic current to modulate neural excitability and brain plasticity [1] .
These non-invasive brain stimulation techniques (NIBS) have been shown to improve depression's symptoms, pain, as well as motor and cognitive deficits [2] [3] [4] [5] . From a clinical perspective, to achieve persisting behavioral effects, participants should attend multiple neurostimulation visits [6, 7] . However, daily visits can be burdensome and might promote low adherence. This decreased adherence is costly, affect intervention's effectiveness, and biases the final potential positive results of an intervention [8] [9] [10] . Various strategies to improve adherence exist, yet there are very few established approaches once a neurostimulation visit is missed [8, 9] .
To study how missed neurostimulation visits are managed, we reviewed randomized clinical trials (RCT) that used tDCS and TMS to treat depression and chronic pain. We first selected depression and we wanted to confront our results with another condition to explore if the issue of missed visits was exclusive of depressive syndromes or may be generalized to other conditions. We selected these conditions since they are highly prevalent and commonly associated with poor adherence (e.g. missed visits) [11, 12] . In addition, these disorders are frequently studied in neurostimulation trials which have shown promising results for symptom reduction (for reviews see [13] [14] [15] [16] [17] ). Based on our findings, we proposed a strategy to handle these missed visits.
Methods
We searched PUBMED/MEDLINE for clinical trials published before 2017, using the keywords: "tDCS", "transcranial direct current stimulation", "transcranial magnetic stimulation¨, "depression", and "pain". Two different searches were performed to reduce the chances to exclude eligible articles. The exact highly sensitive search strategy [18] , can be found in supplementary table 1.
Once the search was performed, we extracted the data and perform of first screening based on the titles and abstracts. Inclusion criteria were: i) Papers written in English; ii) A minimum of 5 tDCS or TMS sessions; iii) A sample size ≥5 participants; iv) Studies on depression or chronic pain. Exclusion criteria were: i) Case reports and case series; ii) Follow-up studies; iii) Observational studies; iv) Articles using the same sample but with different endpoints (only the first published trial was included); v) Animals studies.
For the articles that matched our inclusion and exclusion criteria, a full-text review was done and, if no further exclusion criteria were identified, a quantitative analysis of each article was performed.
This systematic review did not involve human subjects. We only reviewed published articles and data published in these articles. As reviews and meta-analyses do not involve human subjects, they do not require IRB review [19] .
Results

Depression
In total, we extracted 1136 articles that used tDCS and TMS for the treatment of depression. Of these, 112 (fifteen on tDCS and ninety-seven on TMS) matched our inclusion/exclusion criteria and were further quantitatively analyzed (Figure 1 ). After a systematic review of these 112 papers, 9 mentioned missed visits in their protocol. Details regarding each study protocol are reported in Tables 1 and 2 .
Findings' summary
Three out of fifteen articles on tDCS reported the occurrence of missed neurostimulation visits [7, 20] . defined participants who missed three or more consecutive neurostimulation visits out of 12 (25% of missed visits) as drop-outs [7] . These participants were excluded from statistical analyses. Not excluded from analysis were the 103 participants that completed the intervention, where 41 finished all sessions, 37 had one absence and 25 had two.
In the other article, Brunoni et al. (2014) randomized 37 participants, and had 21 dropouts [20] .
Even though the same dropout rule was used, the amount that dropped due to missed neurostimulation visit(s) was not specified. Vanderhasselt et al. (2015) used the same threshold of two consecutive missing sessions, in such cases extra tDCS sessions were performed to complete the total number of sessions [21] . The exact number of patients who missed one or more sessions was not reported. Concerning RCTs on TMS, five articles out of 97 detailed the possibility for patients to miss one or more sessions in their methodology and one article reported missed visits as a reason for dropout in the study flowchart. George et al. (2010) defined completers as patients having less than 4 rescheduled, missed or partially completed sessions, and fully adherent as patients having a maximum of 1 rescheduled, missed, or partially complete sessions (n=15 sessions) [23] . Out of 190 patients, 120 were fully adherent (63%) and 154 were considered as completers (81%). In another trial, George et al. (2014) defined true completers as patients receiving all treatment sessions with the entire number of pulses, even though this was an inpatients study [24] . 27 out of 41 patients were considered as true completers (66%), 9 did not receive the full treatment (22%) and 5 dropped-out (12%). The authors found that the decline in suicidal thinking was more pronounced in the completers group. In another study by Leuchter et al. (2015) , participants underwent 30 TMS sessions (5 per week for 6 weeks) [26] . A maximum of six missed neurostimulation visits was used to define dropout (20% of missed visits). Patients who did not complete 80% of the scheduled sessions were excluded from the analysis (67 out of 202 patients). They also demonstrated that participants needed to receive at least 80% of the rTMS doses (24 out of 30 sessions) to have a statistically significant antidepressant effect. However, neither the rational nor the numbers of dropouts were reported, and replacement of the missed neurostimulation visits was not detailed. Blumberger et al. (2012) allowed a maximum of 2 consecutive sessions to be missed or 4 for the entire protocol consisting of 15 sessions [25] . 30 out of 74 patients did not completed the 6-week protocol; the reasons for drop-outs were not detailed. The same team allowed up to 1 missed session per week (20%) and these sessions were replaced at the end of the protocol [26] . However, the proportion of patients who missed one or more sessions was not described. Finally, Levkovitz et al. (2015) reported in the study flowchart that two participants were excluded from the study after missing two sessions [27] . No further details were described.
Pain
Overall, we extracted 473 articles that studied neurostimulation for the treatment of chronic pain. From these 473 articles, 69 (35 on tDCS and 34 on TMS) matched our criteria and were systematically reviewed ( Figure 2 ). After our quantitative analysis, we only identified 3 articles (4%) mentioning strategies to manage missed neurostimulation visits. The information regarding each study protocol is detailed in tables 3 and 4. only after two or more neurostimulation visits were missed [29] . These visits were never replaced.
Findings' summary:
Out of the 34 trials on TMS, only two of them mentioned management of missed neurostimulation visits. Ambriz-Tutut et al. (2016) removed a subject due to "poor compliance", however they do not explicitly describe their definition of adherence [30] . Malavera et al. (2016) excluded participants that missed one or more day(s) of stimulation [31] .
Discussion
According to the Health World Organization, adherence is defined as, "the extent to which a person's behavior -taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider" [32] , while no specific cut-off for good or poor adherence has been defined yet. Despite the apparent prevalence in clinical research, there is no established gold standard to manage missed visits.
Our analysis of 181 papers revealed that missed visits are widely underreported in NIBS RCTs on depression and chronic pain, since less than 10% of the trials (n=15) mentioned this issue. More precisely, in depression, 8% of the trials reported missed visits and most of them how they managed this issue, while for pain, only 4% of trial did report missed visit but did not provide any further details on how to handle this problem. In studies detailing missing visits, the rate of patients who were not fully adherent is extremely high, ranging from 30 to 60%, reflecting the importance of taking this factor into account when designing a trial and when reporting the results.
Herein, we discuss the importance of missed visit(s) and provide recommendations regarding potential methods to deal with this issue based on the current literature of tDCS and TMS. To do this, we discussed the following questions: Although it is well-defined that multiple sessions of tDCS and TMS have cumulative effects, the impact of spaced sessions in abolishing, potentiating or having no effect still needs to be further clarified [16, [33] [34] [35] . This was explored by Zanão et al. (2014) , based on their previous trial [36] where some patients did not attend all visit [37] . They showed that missing one or two tDCS visits (out of 10) did not alter the treatment effectiveness [37] . Likewise, Leuchter et al. (2015) , demonstrated that participants needed to receive at least 80% of the rTMS doses (24 out of 30 sessions) to have a statistically significant antidepressant effect [26] . In addition, George et al.
(2014) reported that patients receiving the full treatment demonstrated higher improvement in their symptoms as compared to non-completers [24] .
The results from Zanão et al (2014) and Leuchter et al (2015) reflect pharmacological trials' guidelines, in which poor adherence is frequently considered as less than 80% of medication taken correctly [38] . Regardless, there is no universally accepted definition of adequate adherence, despite its potential impact on treatment effectiveness [39] . For instance, if aspirin is taken once a month, it does not prevent myocardial infarction (3% adherence, 1/30 days), while, when it is taken once a week, it can help decreasing the incidence of myocardial infarction (14% adherence, 4/30 days). These properties are summarized in different models by Kravitz et al (2014) . In linear and curvilinear models, the percent of benefit increases as adherence increases. In ON-OFF models, benefit is only achieved when adherence nears 100%.
Finally, in threshold models, benefit is limited below a certain point and maximal above that point [40] . As such, minimum adherence expectations should reflect an intervention's properties and trials' objectives. Under the assumption that tDCS and TMS efficacy follows Kravitz´s models, guaranteeing that the participant receives a sufficient treatment dose to maximize the outcome is relevant [40] [41] [42] [43] . Therefore, based on the reviewed literature, in these populations, and in NIBS trials with at least 5 or more stimulation visits, it seems reasonable to allow up to 20% of neurostimulation visits to be missed.
(ii) Should missed visit(s) be replaced at the end of the stimulation period?
Regarding the studies on tDCS in depression, missed neurostimulation visits were only replaced at the end of the treatment period in three trials [7, 20, 21] . In , only about 40% of the participants received the full intervention as designed, while about 60% had at least one session replaced at the end of the treatment period [7] . Replacement of visits had no impact on the final results as long as the participants were adherent to 80% of the intervention.
To ensure treatment efficacy and that all participants received the same number of treatment sessions, it may be favorable to replace missed visits at the end of the designated stimulation period. In addition, the replacement sessions allow for a more flexible schedule, which could promote increased adherence and reduce the number of dropouts. In order to have a good balance between the flexibility required when working with participants with depression and chronic pain, and the mandatory rigor for RCTs, an additional interval (e.g. 1 week) could be included in the protocol to account for the replacement of missed visits at the end of the planned stimulations session.
To support this recommendationreplacing missing sessions at the end of the stimulation periodone of the trials included in this review compared the efficacy of rTMS when applied every day (5 days per week) for 4 weeks, with rTMS applied every other day (3 days per week) [44] for 6 weeks. After 4 weeks, participants in the daily treatment group, who had received 20 sessions, showed more improvement than participants in the spaced treatment group, who had received 12 sessions, showing the importance of the number of treatments sessions given to induce a significant clinical effect. However, at the end of the 6-week period, once the spaced treatment group had accrued the total 18 sessions, the outcomes were statistically comparable between the two groups (5 days per week vs 3 days per week). The results of this study reflect that spacing the treatments with one day intervals, had no effect on treatment efficacy if the entire number of sessions were provided, which support our recommendation to replace the missed visit at the end of the stimulation period.
In future RCTs, a comparison between the impact of replaced sessions versus nonreplaced session on treatment effectiveness could be a valuable approach to understand this dosing issue. Using the analysis of Leuchter et al (2015) as a model [26] , researchers could compare data collected under per-protocol analysis, to intention to treat analysis and replaced session analysis. This would help to assess the impact of missed visits on clinical outcomes and to find cut-off points for poor adherence.
(iii) When do missed neurostimulation visits bias final results?
Many drug trials report on the effects of poor adherence with a negative impact on the outcomes. For instance, in a multicentric RCT including more than 1000 participants with coronary heart disease, the authors identified a significant difference in term of complications between participants with an adherence of more or less than 75% [45] . They reported that nonadherence (i.e., <75%) was associated with a greater rate of subsequent cardiovascular events, up to two times more than in participants with good adherence (i.e., >75%). In other trials, the threshold is slightly different (e.g., 80% [38] ).
Based on the BCM -Bienenstock, Cooper, and Munroand metaplasticity theories, it can be mentioned that the effects of long-term potentiation (LTP) and long-term depression (LTD) are limited and after a certain number of interventions no further neuroplastic changes are expected [46, 47] . With neurostimulation, hyperactive neurons reduce input by increasing their thresholds (LTP to LTD) while hypoactive neurons do the opposite (LTD to LTP) [47] . This parallels pharmacologic dosing, and drug half-lives, and is a window into understanding dosing mechanisms in NIBS. Briefly, these physiological considerations may support the results seen in 
Conclusion
In future RCTs using neurostimulation, it is important to detail both the timing of missed visit(s) and how this issue was handled when reporting the results. Concerning the impact of missed neuromodulation visits, it would be interesting to compare the results of participants who did not miss any visits versus participants who missed one, two or more visits, if the sample is large enough. This might help researchers and clinicians to understand how missed visits could affect the results and how many treatment sessions could be missed without impacting the outcome. Based on the current literature, allowing 20% of missed visits, while replacing these sessions at the end of the designated stimulation period, seems to be a valuable balance between the rigor requested by RCTs and the expected clinical translation. It also seems to be beneficial as a method to decrease results bias of this important question.
Our review shows that missed visits are an important issue that has not been adequately addressed in neurostimulation RCTs in depression and chronic pain. A better understanding of the impact of missed neurostimulation appointments is essential to avoid erroneous conclusions on its efficacy. This will help scientists and clinicians to understand the genuine impact of nonadherence and establish better strategies that optimize participants' engagement in their treatment.
Expert commentary:
Missed visits are common in neurostimulation trials especially in populations with poor adherence such as depression and chronic pain. In the present review, we noticed that most RCTs did not report missed visits and less than 10% of the RCTs reviewed clearly stated how these missed visits were managed when they occurred. We proposed a plan to handle this issue by allowing up to 20% of appointments to be missed and replacing those visits at the end of the designated stimulations period as successfully done in several RCTs [20, 21, 27, 48] . This method seems to have an appropriate balance between the rigor required in RCT and the flexibility needed for patients with depression or chronic pain, or other conditions inclined to missed treatment visits. On the other hand, we have found evidence that 20% of missed neurostimulation visits may not impact the clinical results [37] . However, nothing is known about the possible impact on the long-term effects of this treatment since the neuroplastic strengthening would not have been as strong as if patients would have received daily stimulation sessions. Future RCTs assessing the effect of 20%, or more, of missed visit need to be conducted including long-term assessments (e.g., 6 months). In our opinion, the duration of the effects is another important point to take into account.
One current limitation of tDCS and TMS use is their unfeasibility to be applied at home, thus, requiring patients to go to laboratories or hospital every day to receive these treatments, which could increase the probability of missing sessions. Therefore, an option to improve adherence to neurostimulation treatments is the development of home-based devices.
We hope that this review will encourage researchers to develop plans to handle missed visits in their protocol and to clearly detail this issue when reporting the results. In addition, we expect that future RCTs comparing different proportions of missed visits on direct and longlasting effects, will help to answer this critical question "how many missed neurostimulation visits will impact the clinical results?" It is essential to tackle this question to facilitate the clinical translation of neurostimulation treatments.
Five Year View
Within the next five years we believe that device trials will develop a clearer understanding of dose-response curves in relation to tDCS and TMS. We expect there to be a minimum and maximum tolerated doses tailored and required per condition. With the development of clinical trials aiming to investigate NIBS dose-response, we will be able to predict the effects of not attending a neurostimulation visit. This will change the interpretation of attrition on outcomes, and statistical methods to handle missing data. It will also create new strategies for administering NIBS and offer new protocol designs options (e.g., allowing one or more missed visit) that might be closer to what is feasible in clinical practice.
Key issues:
 Missed neurostimulation visits occur in non-invasive brain stimulation clinical research.
 There is no standardized method for dealing with missed neurostimulation visits. Some trials exclude the participants immediately, others allow for a predetermined amount of absentee to occur.
 We have found published evidence that 20% of missed neurostimulation visits may be an allowable quantity of absentee, to maintain effects of NIBS.
 However, the long-term effects of missed visits is yet to be determined, and therefore it can be better to replace the missed neurostimulation visit at the end of the neurostimulation period to ensure that all participants receive the same dose of NIBS in a clinical trial.
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